Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Pugliese, N. R., Pellicori, P. , Filidei, F., De Biase, N., Maffia, P. , Guzik, T. J., Masi, S., Taddei, S. and Cleland, J. G.F. (2022) Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovascular Research, 118(18), pp. 3536-3555. (doi: 10.1093/cvr/cvac133) (PMID:36004819) (PMCID:PMC9897694)

[img] Text
276767.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Many patients with symptoms and signs of heart failure have a left ventricular ejection fraction ≥50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogeneous syndrome mainly affecting older people who have many other cardiac and non-cardiac conditions that often cast doubt on the origin of symptoms, such as breathlessness, or signs, such as peripheral oedema, rendering them neither sensitive nor specific to the diagnosis of HFpEF. Currently, management of HFpEF is mainly directed at controlling symptoms and treating comorbid conditions such as hypertension, atrial fibrillation, anaemia and coronary artery disease. HFpEF is also characterised by a persistent increase in inflammatory biomarkers. Inflammation may be a key driver of the development and progression of HFpEF and many of its associated comorbidities. Detailed characterisation of specific inflammatory pathways may provide insights into the pathophysiology of HFpEF and guide its future management. There is growing interest in novel therapies specifically designed to target deregulated inflammation in many therapeutic areas, including cardiovascular disease. However, large-scale clinical trials investigating the effectiveness of anti-inflammatory treatments in HFpEF are still lacking. In this manuscript, we review the role of inflammation in HFpEF and the possible implications for future trials.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Maffia, Professor Pasquale and Cleland, Professor John and Guzik, Professor Tomasz and Pellicori, Dr Pierpaolo
Authors: Pugliese, N. R., Pellicori, P., Filidei, F., De Biase, N., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., and Cleland, J. G.F.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Research Centre:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
Journal Name:Cardiovascular Research
Publisher:Oxford University Press
ISSN:0008-6363
ISSN (Online):1755-3245
Published Online:25 August 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Circulation Research 118(18): 3536-3555
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
308639Defining the individual and integrated roles of inflammatory chemokine receptors (iCCRs) in atherosclerosisPasquale MaffiaBritish Heart Foundation (BHF)PG/19/84/34771CAMS - Cardiovascular Science
309321BHF 4Yr PhD Studentship Award 2109Rhian TouyzBritish Heart Foundation (BHF)FS/19/56/34893CAMS - Cardiovascular Science
313479Defining AXL Role in AtherosclerosisPasquale MaffiaBritish Heart Foundation (BHF)PG/21/10541CAMS - Cardiovascular Science
314413Defining the IL-21/IL-21 receptor axis role(s) in atherosclerosisPasquale MaffiaBritish Heart Foundation (BHF)PG/21/10634CAMS - Cardiovascular Science
300798A study of the roles of the immune and inflammatory systems in hypertensionTomasz GuzikEuropean Research Council (ERC)726318CAMS - Cardiovascular Science